6:01 PM · 13 April 2021

Moderna stock rose 7% after FDA halt use of JNJ vaccine

Moderna
Stocks
MRNA.US, Moderna Inc
-
-
J&J
Stocks
JNJ.US, Johnson & Johnson
-
-

The news that the Johnson & Johnson (JNJ.US) vaccine would be paused appeared to be beneficial for Moderna (MRNA.US) which shares gained more than 7% following FDA announcement. The drugmaker has also issued a statement saying that data indicates its COVID-19 vaccine is not associated with cerebral venous sinus thrombosis ("CVST") or other thrombotic events. Moderna announced that assessment was made based on safety data through March 22 of more than 64.5M doses administered worldwide.

Moderna (MRNA.US) stock launched today's session with a bullish price gap and is currently testing the upper limit of the descending channel which coincides with 50 SMA (green line). Source: xStation5

16 October 2025, 3:28 PM

Stock of the Week - Lam Research Corp (16.10.2025)

16 October 2025, 3:02 PM

Salesforce surges 8% amid positive long-term revenue forecast📈

16 October 2025, 1:41 PM

Thermo Fisher Scientific announces strategic collaboration with OpenAI📱

16 October 2025, 12:49 PM

DE40: Europe moves sideways, Nestle gains

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits